Etacizin

Olpha to introduce a new diabetes medicine in the Baltics in partnership with international pharmaceutical company Adalvo

26th of October, 2026

Latvian pharmaceutical manufacturer Olpha has signed a cooperation agreement with Switzerland-based international pharmaceutical company Adalvo to introduce a new medicine for the treatment of type 2 diabetes and weight management in the Baltic markets. The partnership will expand Olpha’s diabetes treatment portfolio.

Read article

26th of October, 2026

Olpha to introduce a new diabetes medicine in the Baltics in partnership with international pharmaceutical company Adalvo

Read

21st of August, 2026

Olpha to Invest EUR 5.84 Million in Expanding Its Manufacturing Facility for New Products

Read

7th of May, 2026

From China to Latvia: Hao Zhang’s Internship Experience at Olpha

Read

Etacizin

Olpha to introduce a new diabetes medicine in the Baltics in partnership with international pharmaceutical company Adalvo

Olpha to introduce a new diabetes medicine in the Baltics in partnership with international pharmaceutical company Adalvo

From Architecture and Business to Pharmaceuticals: The Courage to Start Over

Marks Major Construction Milestone for New Manufacturing Facility

Olpha Expands Its Over-the-Counter Portfolio with a New Pain Relief Medicine

Olpha to Expand Exports of Pharmaceutical Research and Development Services

Olpha to Invest EUR 5.84 Million in Expanding Its Manufacturing Facility for New Products

From China to Latvia: Hao Zhang’s Internship Experience at Olpha

Cooperate with Olpha

Attention!

Are you a health care worker?